糖尿病管理干预研究:两项研究的经验教训
本文基于STeP和ProValue两项研究,讨论依赖行为改变的医疗器械干预研究在实施与解读中的挑战。文章建议优先保障医护人员参与、提供技术操作支持并详细评估依从性,同时强调分配隐藏、识别对照组改善原因及试点研究的重要性。结论指出对照组改善可能缩小效应量并限制统计显著性,可考虑传统随机对照试验的替代方案。
要点
- 依赖行为改变的干预研究需优先保障医护人员参与和技术支持。
- 应严格分配隐藏以避免对照组沾染干预,并详细评估依从性。
- 对照组改善常源于霍桑效应,需识别原因并调整流程,试点研究不可或缺。
核心结论
- 依赖行为改变的医疗器械干预研究需综合考虑多个实施方面以取得显著结果。
- 对照组改善可能缩小效应量并限制统计显著性,可考虑传统随机对照试验的替代方案。
研究设计与样本
- 本文为基于STeP和ProValue两项研究经验的方法学论述,非系统综述或指南。
主要发现
- STeP和ProValue研究的经验表明,依赖干预组患者行为改变的医疗器械研究存在困难。
- 对照组因霍桑效应或受试者关注增加而出现临床终点改善,可导致效应量受限。
- 随机化和盲法并非总是可行。
临床怎么用
- 应优先确保医护人员参与、提供技术问题操作支持并详细评估依从性。
- 应保持严格分配隐藏以避免对照组沾染干预。
- 应识别对照组改善的具体原因并调整研究流程,试点阶段不可或缺。
- 可考虑设置第三研究组以控制增强的标准化诊疗和研究效应,或采用回顾性数据收集。
- 自适应设计可能减少单独试点研究的必要性,并将探索性与确证性阶段合并。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Several clinical studies investigated improvements of patient outcomes due to diabetes management interventions. However, chronic disease management is intricate with complex multifactorial behavior patterns. Such studies thus have to be well designed in order to allocate all observed effects to the defined intervention and to exclude effects of other confounders as well as possible. This article aims to provide challenges in interpreting diabetes management intervention studies and suggests approaches for optimizing study implementation and for avoiding pitfalls based on current experiences. MAIN BODY: Lessons from the STeP and ProValue studies demonstrated the difficulty in medical device studies that rely on behavioral changes in intervention group patients. To successfully engage patients, priority should be given to health care professionals being engaged, operational support in technical issues being available, and adherence being assessed in detail. Another difficulty is to avoid contamination of the control group with the intervention; therefore, strict allocation concealment should be maintained. However, randomization and blinding are not always possible. A limited effect size due to improvements regarding clinical endpoints in the control group is often caused by the Hawthorne effect. Improvements in the control group can also be caused with increased attention paid to the subjects. In order to reduce improvements in the control group, it is essential to identify the specific reasons and adjust study procedures accordingly. A pilot phase is indispensable for this. Another option is to include a third study arm to control for enhanced standard of care and study effects. Furthermore, retrospective data collection could be a feasible option. Adaptive study designs might reduce the necessity of a separate pilot study and combine the exploratory and confirmatory stages of an investigation in one single study. CONCLUSION: There are several aspects to consider in medical device studies when using interventions that rely on changes in behavior to achieve an effective implementation and significant study results. Improvements in the control group may reduce effect sizes and limit statistical significance; therefore, alternatives to the traditional randomized controlled trials may be considered.
引用
- Petersen B, Vesper I, Pachwald B, et al. Diabetes management intervention studies: lessons learned from two studies. Trials. 2021. PMID: 33461624. doi:10.1186/s13063-020-05017-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。